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Introduction: Approximately 100 loci have been definitively associated with rheumatoid arthritis (RA) susceptibility.
However, they explain only a fraction of RA heritability. Interactions between polymorphisms could explain part of
the remaining heritability. Multiple interactions have been reported, but only the shared epitope (SE) × protein
tyrosine phosphatase nonreceptor type 22 (PTPN22) interaction has been replicated convincingly. Two recent
studies deserve attention because of their quality, including their replication in a second sample collection. In one
of them, researchers identified interactions between PTPN22 and seven single-nucleotide polymorphisms (SNPs).
The other showed interactions between the SE and the null genotype of glutathione S-transferase Mu 1 (GSTM1) in
the anti–cyclic citrullinated peptide–positive (anti-CCP+) patients. In the present study, we aimed to replicate
association with RA susceptibility of interactions described in these two high-quality studies.
Methods: A total of 1,744 patients with RA and 1,650 healthy controls of Spanish ancestry were studied.
Polymorphisms were genotyped by single-base extension. SE genotypes of 736 patients were available from
previous studies. Interaction analysis was done using multiple methods, including those originally reported and the
most powerful methods described.
Results: Genotypes of one of the SNPs (rs4695888) failed quality control tests. The call rate for the other eight
polymorphisms was 99.9%. The frequencies of the polymorphisms were similar in RA patients and controls, except
for PTPN22 SNP. None of the interactions between PTPN22 SNPs and the six SNPs that met quality control tests was
replicated as a significant interaction term—the originally reported finding—or with any of the other methods. Nor
was the interaction between GSTM1 and the SE replicated as a departure from additivity in anti-CCP+ patients or
with any of the other methods.
Conclusions: None of the interactions tested were replicated in spite of sufficient power and assessment with
different assays. These negative results indicate that whether interactions are significant contributors to RA
susceptibility remains unknown and that strict standards need to be applied to claim that an interaction exists.* Correspondence: antonio.gonzalez.martinez-pedrayo@sergas.es
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Progress in the genetics of complex diseases such as
rheumatoid arthritis (RA) has been very rapid in the last
decade [1]. Many loci have been discovered that are con-
vincingly and reproducibly associated with susceptibility
to these diseases. About 100 loci are associated with RA
susceptibility at the genome-wide association study
(GWAS) level [2]. However, the advance in genetics has
also shown that there are still many remaining chal-
lenges. One that has been the focus of much discussion
is the large fraction of the genetic component that is still
unknown. This fraction has been dubbed as missing
heritability that for most complex diseases is larger than
50% [3]. The exact magnitude of missing heritability is
disputable because of ambiguity in the estimation of the
total heritability that needs to be explained [4]. In a
study estimating heritability from GWAS data, a method
that is not affected by genetic interactions, but that is in-
sensitive to low frequency causal loci, the 100 known
non–human leukocyte antigen (non-HLA) loci account
for 4.7% to 5.5% of RA heritability [2]. This fraction has
been reported to be smaller (about 2.5%) in twin studies
[5], which are susceptible to confounding by genetic
interactions but sensitive to low-frequency loci [4]. In
addition, the large heterogeneity of RA adds to the
ambiguity of the magnitude of missing heritability, as
shown by the different genetic contributions of HLA
shared epitope (SE) alleles in anti–cyclic citrullinated
peptide–positive (anti-CCP+) patients (18%) and in anti-
CCP− patients (2.4%) [6]. Therefore, the missing herit-
ability is very considerable in RA independently of the
method used to estimate total heritability and the sub-
group of patients being considered.
A variety of hypotheses have been proposed to explain
the missing heritability [3], and there are already some
studies in which researchers are exploring them in RA
and other complex diseases [5,7-9]. One of these hypoth-
eses is very compelling from a biological point of view. In
that hypothesis, molecules, cells or tissues interact, and
the outcome is often not fully predictable on the basis of
consideration of the isolated factors. These ideas apply
also to genes, whose products interact with the products
of other genes and with the environment in gene × gene
and gene × environment interactions, respectively. These
interactions have been studied for a long time in genetics,
but research in complex diseases has introduced in this
field a strong incentive for more study together with the
many difficulties typical of these diseases [10-13].
Interactions are invoked as a possible explanation for
missing heritability because the combined effect of two
genes can be larger than the sum of their individual con-
tributions. In addition, genes that are not associated with
disease susceptibility when considered in isolation can
be associated in the presence of a modifier allele of othergene. Therefore, part of the missing heritability can
be hidden in the form of interactions of known loci,
because their contribution is considered one by one, as
well as in loci not yet identified, because researchers in
most GWASs have searched for associations single-
nucleotide polymorphism (SNP) by SNP. It is also likely
that the discovery of interactions will be of great utility
for understanding the mechanisms of disease and to find
very sensitive steps for therapeutic intervention. This
hypothesis has driven multiple efforts to define types of
interaction and their meaning and interpretation, as well
as to develop tools to study them. Thanks to these
efforts, there has been notable progress with tools that
can be used to assess the association of all pairs of SNPs
in a GWAS [14], as well as with statistical tests for inter-
action with increased sensitivity [10,15,16]. There has
been also considerable clarification of the definitions and
interpretation of the different types of interaction [10,13].
Research in RA has had an important role in the re-
cent progress in the study of interactions in complex
diseases. It has led to the discovery of one of the most
reproducible examples: interaction between HLA-DRB1
SE and protein tyrosine phosphatase nonreceptor type
22 (PTPN22) risk genotypes and with smoking in anti-
CCP+ patients [17]. These interactions have been widely
replicated [18-20] and also have introduced interaction
as a departure from additivity, the less well-known type
of interaction [21], to the complex disease genetics field.
However, the progress in interaction analysis has not yet
translated to frequent attempts to replicate previous
findings; therefore, the multiple interactions in RA that
have been reported in the main genetics and rheuma-
tology journals [22-31] remain without confirmation.
We aimed to replicate sound studies of gene × gene
interactions in the genetics of RA. We selected two
studies that included both discovery of interaction and
its replication in additional samples [22,23]. One of
them included testing of many pairwise interactions, and
therefore multiple tests, but the authors corrected for
them by proceeding in four selection steps in three dif-
ferent sample collections [22]. This first study led to the
identification of seven SNPs showing multiplicative in-
teractions with PTPN22 that passed the four filters. In
the second study, the authors analyzed only a gene ×
gene interaction and included replication in a second
collection of samples [23]. The null genotype of glutathi-
one S-transferase Mu 1 (GSTM1) showed additive inter-
action with the SE carrier genotype in the comparison of
anti-CCP+ and anti-CCP− patients. Our study did not
replicate any of these interactions in spite of its sufficient
power and the use of additional powerful tests. There-
fore, we still need to find out how to improve reproduci-
bility of interaction studies before knowing whether they
are a significant contribution to RA susceptibility.
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Participants
DNA samples from patients with RA and healthy con-
trols were obtained as described previously [32]. All par-
ticipants were of European Spanish ancestry. Briefly, the
study included a total of 1,744 patients classed with RA
according to the 1987 American College of Rheu-
matology criteria [33] and 1,650 healthy controls. All
recruiting centers applied a questionnaire that asked all
participants about demographic data, including the ori-
gin of their progenitors. Those reporting a non-Spanish
progenitor at any level were excluded. The Ethics Com-
mittee for Clinical Research of Galicia approved this
study, and the ethics committees at the recruiting cen-
ters (listed in the Appendix) approved sample collection.
All participants gave their written informed consent.
Clinical data for the patients, including the anti-CCP
and HLA-DRB1 genotypes of 736 patients, were ex-
tracted from their clinical records or from previous stu-
dies [20] (Table 1).
Genotyping assays
The RA-associated PTPN22 SNP rs2476601 (R620W)
and the seven SNPs that have epistasis with it according
to Briggs et al. [22], and an insertion/deletion poly-
morphism of exons 4 and 5 of GSTM1 determining the
native and null alleles that interact with SE according to
Mikuls et al. [23], were studied with single-base exten-
sion assays (SNaPshot Multiplex Kit; Life Technologies,
Carlsbad, CA, USA) applied to the products of a
multiplex PCR carried out with the KAPA2G Fast
HotStart enzyme (Kapa Biosystems, Wilmington, MA,
USA). Detailed protocols, as well as the sequences ofTable 1 Clinical features of the patients with rheumatoid
arthritisa
Clinical characteristics RA patients
Women (%) 75.7
Median age at disease onset (IQR)b 47 (37 to 57)
Morning stiffness (%) 96.2
Arthritis in three or more joint areas (%) 99.7
Arthritis of hand joints (%) 99.3
Symmetric arthritis (%) 99.1
Rheumatoid nodules (%)b 20.3
Rheumatoid factor (%) 71.2
Erosions (%) 68.6
Sicca syndrome (%) 8.9
Interstitial pneumonitis (%) 2.7
Shared epitope (carrier %)b 55.0
Anti-CCP (%)b 67.3
aCCP, Cyclic citrullinated peptide; RA, Rheumatoid arthritis. bData were
available for <85% of the patients: 1,349 for age of disease onset, 1,283 for
rheumatoid nodules and 736 for shared epitope and anti-CCP antibodies.primers and probes used for these assays, are available
upon request. Only the GSTM1 polymorphism was un-
common, because, as in previous studies [23], it did not
allow detection of heterozygous participants; only null ho-
mozygotes could be distinguished from carriers of native
alleles. Quality control procedures used included manual
revision of results, call rate >90% for each polymorphism,
fit of genotype frequencies with Hardy-Weinberg equili-
brium (HWE) (P >0.05), reproducibility (>99%) tested by
regenotyping 10% of the samples, and comparison of allele
frequencies with those in HapMap and with those re-
ported in other studies.
Statistical analyses
Allelic association of each polymorphism with RA suscep-
tibility was assessed with χ2 tests. Replication of previously
reported interactions was attempted first with the same
statistical analysis used in the original study and afterward
with alternative approaches. In this way, the multiplicative
interaction between PTPN22 rs2476601 and each of the
other seven SNPs described by Briggs et al. [22] was tested
as the coefficient of the multiplicative interaction term of
a logistic regression model that included the PTPN22 SNP
and the interacting SNP coded according to a dominant
model of their minor alleles. This coefficient is equal to
the ratio of odds ratios of the interaction (RORi). This
analysis was done by comparing RA patients with con-
trols; also, anti-CCP+ patients were compared with healthy
controls, because most patients in the Briggs et al. study
were anti-CCP+. All the previous analyses were performed
with STATISTICA software (StatSoft, Tulsa, OK, USA). In
turn, interaction analysis between the GSTM1 null geno-
type and the SE was performed as described by Mikuls
et al. [23]. That is, we compared anti-CCP+ patients with
anti-CCP− patients following a dominant model for the
GSTM1 native and HLA-DRB1 SE alleles. The parameter
analyzed was the attributable proportion (AP) to the
interaction [21]. When AP is different from zero, it indi-
cates the proportion of the association of the two loci
that is attributable to departure from additivity. This
analysis was done in R [34] using the Hosmer and
Lemeshow approach [35].
The alternative approaches for analysis of the inter-
action included interchanging the analyses and other
complementary tests—that is, testing the interactions
used by Briggs et al. for departure from additivity and
testing the relationship between the GSTM1 null geno-
type and SE as a multiplicative interaction. These tests
were complemented with others. First, we tested multi-
plicative interactions with the same three-term logistic
regression model, but with the polymorphisms coded
according to an additive genetic model (codes 0, 1 and 2
for the common allele homozygote, the heterozygote
and the minor allele homozygote, respectively). Second,
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rated genetic models with and without interactions [36].
These models are built as logistic regression models, and
the best model is selected by using Akaike’s Information
Criterion (AIC), which is more sensitive than a signifi-
cant difference between models. Models having an AIC
difference <2 are not meaningfully different. Third, we
performed two tests that, according to recent comparative
studies, are the most powerful for detecting multiplicative
interaction between two loci in a series of scenarios, pro-
vided that the two loci are in linkage equilibrium [15,16].
The first was the chi-squared Pearson statistic (TPearson) in
cases for independence of two loci [15]. The second was
the adjusted Wu statistic for gametic phase disequilibrium
in case-only analysis (TAWu-co) [16]. Power analysis was
done applying the formula for power of RORi [37].
Results
Genotyping assays for one of the SNPs (rs4695888, se-
lected for its reported interaction with PTPN22) failed.
The remaining polymorphisms were successfully assayed
in 99.9% of the Spanish samples. Genotypes of all them
fitted HWE (P <0.05). Only PTPN22 rs2476601 of the
SNPs from Briggs et al. was significantly associated with
RA (OR = 1.53, 95% CI = 1.29 to 1.80, P = 4.61 × 10−7)
(Table 2). Lack of association of the other SNPs was also
the result in a previous report [22]. The GSTM1 null
genotype, in turn, was not different between anti-CCP+
and anti-CCP− RA patients (Table 2, lower rows),
whereas the SE was clearly more common in the anti-
CCP+ patients than in the anti-CCP− patients. These re-
sults are similar to those previously reported by Mikuls
et al. [23].Table 2 Association of polymorphisms with rheumatoid arthr
rheumatoid arthritisa
RA patients Contro
SNP Genotype counts MAF Genoty
PTPN22 rs2476601 1,383/325/35 0.11 1,405/2
rs7726839 1,012/631/100 0.24 959/59
rs12573019 1,302/405/37 0.14 1,264/3
rs1168587 652/830/260 0.39 612/76
rs1895535 1,602/138/4 0.04 1,503/1
rs7200573 940/687/116 0.26 890/63
rs11865624 1,532/201/10 0.06 1,424/2
Anti-CCP+ patients Anti-C
Positive/negative Positiv
SE 279/174b 116/15
GSTM1 402/376c – 186/19
aComparison of patients with rheumatoid arthritis (RA) and healthy controls for the
upper rows and comparison between anti–cyclic citrullinated peptide–positive (ant
S-transferase Mu 1 (GSTM1) in the lower rows. MAF, Minor allele frequency; ns, Not
bPositive, SE carrier; negative, SE non-carrier. cPositive, native carrier; negative, nullLack of replication of epistasis with PTPN22 rs2476601
We tested the reported epistasis between six SNPs and
the PTPN22 rs2476601 SNP according to the original
model: multiplicative interaction (evaluated as the inter-
action term of a logistic regression or its equivalent
RORi between the minor alleles following dominant in-
heritance [22]. These analyses did not replicate any of
the six instances of epistasis (Table 3). Lack of replica-
tion was not attributable to lack of power, because the
post hoc type II errors (β) of missing results of a magni-
tude as the reported by Briggs et al. [22] at the final
stage of their analyses were <0.20, which is convention-
ally considered sufficient (corresponding to statistical
power of 0.80). The SNP with less power at the RORi
term was rs7726839 with post hoc β =0.136, whereas all
others had post hoc β <0.071.
A lack of significant epistasis was observed, both with
all patients and with anti-CCP+ patients. The lack of
replication of epistasis was not dependent on the type of
specific test or interaction model, because we tested the
six SNPs for multiplicative interaction with the PTPN22
rs2476601 SNP using several methods and none was
positive (not shown). These tests included different ge-
netic models in addition to the dominant one explored
in the original report [22]. They also included the two
tests reported as the most powerful in recent comparative
studies [15,16]. In addition, we tested the six SNPs for
interactions with PTPN22 in the alternative framework for
interaction, as a departure from additivity, and obtained
similar results. We should note that, in addition to not
showing significant association, the RORi of each of the
six SNPs showed a nominal change in the opposite
direction to the previously reported data (Figure 1).itis or anti–cyclic citrullinated peptide–positive
ls
pe counts MAF P OR (95% CI)
35/10 0.08 4.61 × 10−7 1.53 (1.29 to 1.8)
2/88 0.23 ns 1.02 (0.91 to 1.14)
59/27 0.13 ns 1.11 (0.97 to 1.28)
2/276 0.40 ns 0.97 (0.87 to 1.05)
37/7 0.05 ns 0.91 (0.72 to 1.15)
3/127 0.27 ns 0.97 (0.87 to 1.08)
21/3 0.07 ns 0.92 (0.76 to 1.11)
CP− patients
e/negative
3b 1.69 × 10−6 2.11 (1.56 to 2.88)
2c – ns 1.10 (0.86 to 1.41)
single-nucleotide polymorphisms (SNPs) from Briggs et al. [22] in the
i-CCP+) and anti-CPP− RA patients for shared epitope (SE) and glutathione
significant; PTPN22, Protein tyrosine phosphatase nonreceptor type 22.
homozygote.
Table 3 Lack of replication of epistasisa as the described by Briggs et al. [22]
SNP RORi (95% CI) P SNP carriers SNP noncarriers Anti-CCP
+ patients
ORPTPN22 (95% CI) ORPTPN22 (95% CI) RORi (95% CI) P
rs7726839 1.08 (0.75 to 1.55) 0.70 1.56 (1.18 to 2.07) 1.45 (1.15 to 1.83) 1.23 (0.8 to 1.9) 0.34
rs12573019 0.74 (0.49 to 1.12) 0.15 1.19 (0.83 to 1.71) 1.61 (1.31 to 1.98) 0.63 (0.38 to 1.04) 0.07
rs1168587 0.84 (0.58 to 1.22) 0.35 1.40 (1.11 to 1.76) 1.68 (1.24 to 2.24) 0.92 (0.59 to 1.43) 0.71
rs1895535 0.66 (0.36 to 1.20) 0.17 1.02 (0.58 to 1.80) 1.56 (1.25 to 1.92) 0.84 (0.39 to 1.8) 0.66
rs7200573 1.14 (0.8 to 1.63) 0.47 1.60 (1.24 to 2.07) 1.40 (1.10 to 1.80) 1.26 (0.82 to 1.93) 0.28
rs11865624 1.15 (0.68 to 1.94) 0.59 1.69 (1.04 to 2.75) 1.47 (1.21 to 1.78) 1.35 (0.72 to 2.53) 0.36
aData show lack of replication between the six single-nucleotide polymorphisms (SNPs) and the PTPN22 rheumatoid arthritis (RA) locus in the whole set of RA pa-
tients and controls (left) and in the comparison of anti–cyclic citrullinated peptide–positive (anti-CCP+) patients with controls (last two columns on the right).
PTPN22, Protein tyrosine phosphatase nonreceptor type 22; RORi, Ratio of odds ratios of the interaction.
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and the shared epitope
Interaction between the null genotype of GSTM1 and
that carrying the SE has been described as a significant
additive interaction in comparisons between anti-CCP+
and anti-CCP− patients with RA [23]. In our samples,
there was no evidence of this interaction, as the AP
was not significantly different from zero (AP = −0.05,
95% CI = −0.54 to 0.44). None of the additional tests per-
formed for deviations from additivity (relative excess risk
due to interaction RERI and synergy [SI]) were signifi-
cant, and neither were the tests used to assess multi-
plicative interactions (not shown), which were the sameFigure 1 Comparison of the multiplicative interaction terms (ratio of
Briggs et al. [22]. None of the 95% CIs from Briggs et al. cross the 1.0 line
cross this line and show a nominal opposite direction. RORi, Ratio of oddsas those described in the previous subsection. In ex-
ploratory analysis, the OR for the patients with the
GSTM1 native genotype and SE was identical to the OR
for the patients with the GSTM1 null genotype and SE,
reflecting the lack of increased association when the two
risk genotypes were present (Table 4). Lack of sufficient
power for replication was unlikely, because the sample
sizes of the two collections of samples used by Mikuls
et al. [23] were slightly smaller than those available to us
(703 from the Veterans Affairs Rheumatoid Arthritis
(VARA) registry and 610 from the Study of New-Onset
Rheumatoid Arthritis (SONORA) sample set, compared
to 721 in the present study). We applied analysis ofodds ratios of the interaction) from the present study and from
, showing that they are significant. All the CIs from the present study
ratios of the interaction.
Table 4 Analysis of interaction between GSTM1 genotype
and HLA-DRB1 shared epitope carrier status in comparison
of anti-CCP+ with anti-CCP− rheumatoid arthritis patientsa
GSTM1/SE Anti-CCP+/anti-CCP− (n) OR (95% CI)
Native/SE− 84/79 Reference
Null/SE− 90/74 1.14 (1.77 to 0.74)
Native/SE+ 130/54 2.26 (1.46 to 3.52)
Null/SE+ 148/62 2.25 (1.46 to 3.44)
aCCP, Cyclic citrullinated peptide; GSTM1, Glutathione S-transferase Mu 1;
GSTM1 native, Carrier native; GSTM1 null, Homozygote null; SE, Shared epitope.
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[38,39], owing to the lack of an analytical approach for es-
timating the power of AP. This analysis showed that our
results were sufficient to exclude an interaction as the ob-
served in the VARA sample, because the APs of the two
studies fall outside the respective CIs (Figure 2). In con-
trast, our results were uncertain (neither excluding nor
declaring them equivalent) in relation to the interaction
observed in the SONORA sample, because the AP of the
SONORA sample was within the CI of our study but the
AP of our study is outside the CI of the SONORA sample
(Figure 2).Figure 2 Comparison of attributable proportions to interactions. Grap
the GSTM1-null genotype and shared epitope in anti–cyclic citrullinated pe
the two sample collections (Veterans Affairs Rheumatoid Arthritis (VARA) regis
included in the Mikuls et al. study [23].Discussion
None of the seven interactions analyzed was replicated.
This is very significant because (1) they have been re-
ported in large studies that included replication in inde-
pendent samples [22,23], and (2) our study is of
sufficient power, we performed analyses for multiple in-
heritance and interaction models and we used the most
powerful tests [15,16]. Therefore, we think our results
raise questions about these interactions and, more gen-
erally, that they show how the level of reproducibility
reached in RA association studies has yet to be achieved
in interaction studies. As a consequence, only the previ-
ously known SE × PTPN22 interaction pertaining to
anti-CCP+ RA patients remains independently validated
among the gene × gene interactions [17].
We attempted to replicate the Briggs et al. study
where the authors have considered the whole genome
for interactions with PTPN22 [22]. As such, the number
of tests could be very large and led to many false posi-
tives, but the Briggs et al. study included four steps of
filtering. In the first step, 512 multiplex RA families were
studied with microsatellites covering the genome. This
analysis led to suggestive evidence in 5 loci containing
10,589 SNPs of the GWAS platform. These SNPs wereh depicts the attributable proportions to the interaction (APs) between
ptide–positive rheumatoid arthritis patients in the present study and
try and Study of New-Onset Rheumatoid Arthritis (SONORA) sample set)
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trols from the North American Rheumatoid Arthritis Con-
sortium I (NARAC-I)) for significant heterogeneity of
PTPN22 association in function of the SNP genotypes.
The 665 SNPs showing significant heterogeneity were
tested for multiplicative interaction in the subset of the
NARAC-I sample with a more uniform Northern Euro-
pean ancestry. In this subset of 677 patients and 750 con-
trols, the number of SNPs showing significant interaction
was 449. These SNPs were tested again in an additional
set of 947 patients and 1,756 controls (NARAC-II). Sig-
nificant interactions were replicated for the seven SNPs
we addressed in the present study. The least significant
RORi showed a P =6.1 × 10−3 in the joint analysis of the
two last case–control sets. Therefore, none of them was
borderline significant; however, none was extremely sig-
nificant, because the lower P-value was 1.5 × 10−5. In
retrospect, it seems likely that the multiple filters were not
sufficient to eliminate false-positive results although they
reduced them. This makes it necessary to consider that
joint analysis of all available samples with a higher thresh-
old of significance could be more efficient for interaction
analysis, as it is for association studies [40].
The Mikuls et al. study was hypothesis-driven, and the
researchers examined a single gene × gene interaction
[23]. Their aim was to explore the null genotype of
GSTM1 with regard to susceptibility to anti-CCP+ RA.
The GSTM1 null allele determines a deletion of the glu-
tathione S-transferase gene, coding for a ubiquitous
enzyme facilitating elimination of reactive oxygen species
conjugated to glutathione. The null genotype has been
associated with higher oxidative stress and increased risk
for smoking-related inflammatory diseases, including RA
[41-43]. Therefore, the hypothesis of Mikuls and col-
leagues was that the null genotype of GSTM1 contributes
to anti-CCP+ RA where smoking is known to increase
risk. Analysis of the 703 patients of the VARA collection
showed additive interaction between the GSTM1 null
genotype and SE when comparisons of the anti-CCP+ with
the anti-CCP− patients were made [23]. This result was
replicated in the 610 patients of the SONORA study.
Additive interactions are known between PTPN22 and
SE and between SE and smoking in the anti-CCP+
RA patients [17-20]. This type of interactions has
been claimed to be more biologically relevant than
multiplicative interactions [17,21], although there is a
lot of discussion about the meaning of any of them
[10,13]. Therefore, Mikuls et al. apparently found an
additional piece of the network of interacting factors
leading to anti-CCP+ RA [23]. However, it is note-
worthy that they did not find interactions with smok-
ing, which was another piece of the hypothesis and
one that was relevant in other RA studies [41,43].
Our study did not replicate the interaction betweenGSTM1 and SE in spite of the sufficient power and
multiple tests for interaction.
It has been proposed that replicating gene × gene in-
teractions is more difficult than replicating associations
of individual SNPs. The additional difficulty is due in
part to the study of polymorphisms that are not causal
of the interaction, but only in linkage disequilibrium
(LD) with the nongenotyped causal polymorphisms
(markers or tags) [44]. The power of the replication is
decreased by variation in the LD of the genotyped tag
SNPs with the causal polymorphisms between the sam-
ples used for discovery and for replication. The re-
duction of power is proportional to the product of the
decreasing LD between tag SNPs and the causal variants
[44]. This factor is moderated in our study because
PTPN22 rs2476601, the SE alleles and the null genotype
of GSTM1 are causal polymorphisms, leaving no room
for this effect in the interaction that was described by
Mikuls et al. [23], and only for a linear decrease in
power with the decrease in LD in the SNPs reported as
interacting with PTPN22 [22]. Another factor contribut-
ing to the lack of reproducibility is heterogeneity be-
tween studies. However, genetic heterogeneity does not
have a large impact in RA, where most loci are shared
between Europeans and Asians [2]. Therefore, it is un-
certain if the lower frequencies of carriers of PTPN22
rs2476601 and SE in our Spanish patients compared to
patients in the previous studies conducted with partici-
pants of Northern European ancestry could have con-
tributed to the discordant results (PTPN22 risk allele
carriers in our RA patients =20.7% vs. 27.8% and 27.3%
in NARAC-I and NARAC-II, respectively, P <10−4 for
both comparisons; and 54.6% of SE carriers in our RA
patients vs. 75.5% and 71.1% in the VARA and SONORA
samples, P <10−15 and P <10−9, respectively). Another
type of heterogeneity that decreases reproducibility is
clinical heterogeneity. In this regard, within the available
information, we note only a much rarer smoking habit
in our patients than in the patients in the Mikuls et al.
study (20.6% of ever smokers among the RA patients we
analyzed for this interaction vs. 79.8% and 65.1% in the
VARA and SONORA cohorts, P <10−93 and P <10−50,
respectively). Other differences, such as in the sex ratios,
were observed only between our samples and one of the
two collections used in the previous studies. Again, it is
uncertain if the difference in smoking habit could im-
pinge upon the results because no interaction between
smoking and GSTM1 null genotype was detected by
Mikuls et al. [23]; however, such an interaction was re-
ported in a different RA study [41].
The negative results we have obtained are discouraging
because we selected for replication studies that were
prominent in their methods and results, and because
there is a conflict between biologic concepts that include
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in association studies. There are many other studies in
which researchers have reported significant gene × gene
interactions in RA [24-31], but only the PTPN22 × SE
interaction in anti-CCP+ patients has been indepen-
dently replicated [17-20]. It has been a constant in the
field to hope that better methods will allow discovery of
prevalent interactions, but this hope has yet to be
realized. Lack of reproducibility has also been observed
between analyses of the same data with different ap-
proaches, as has happened with the Welcome Trust
Case Control Consortium GWAS of seven complex dis-
eases, including RA [14,45,46], and with the NARAC
GWASs [47-50]. Therefore, it is not attributable only to
insufficient power of the studies. Over time, it is becom-
ing evident that discovery of interactions is a standing
challenge for the genetics of complex diseases. Until a
solution is found, researchers have no better choice than
to increase demands on the threshold for significance
and on independent replication for the assessment of
interaction findings. It is to be expected that these mea-
sures will help to uncover the contribution that interac-
tions have on the genetic components of RA and how
these components work.
Conclusion
No new gene × gene interactions in the susceptibility to
RA have been independently replicated beyond the inter-
action between the SE and the risk allele of PTPN22. Our
selection of two sound studies for replication led to nega-
tive results. The lack of interaction was found in spite of
sufficient power and thorough analysis. This situation is
unsatisfactory because interactions are widespread in bio-
logical systems, and they could help answer many ques-
tions, including the heritability not explained by known
disease loci. Our negative results show that the contri-
bution of genetic interactions to RA susceptibility still
cannot be assessed and that strict standards for claiming
interactions need to be applied.
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